← Leaderboards
James M Olson
Seattle Children'S Hospital
$23,190,448
Attributed
$27,944,119
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,944,119 · 13
By mechanism
R01$18,709,412 · 7
U01$5,147,430 · 2
R44$2,056,262 · 1
R42$1,361,629 · 1
R21$503,194 · 1
T32$166,192 · 1
Top collaborators
- Roland K Strong5 shared
- Vandana Kalia4 shared
- Andrew J. Mhyre3 shared
- Richard Klinghoffer2 shared
- Franck K Kalume1 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorClinical TrialsOperative Surgical ProceduresToxic EffectChemotherapyIn VivoPharmaceutical PreparationsMedulloblastomaMalignant NeoplasmsNeoplastic CellCancer CellChildCellsRadiationMolecularChildhoodPre-ClinicalChildhood Brain NeoplasmBrain NeoplasmsBaseExcisionDrug CandidateResistanceClinical Data
Grant awards (65)
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma$851,913
U01 · FY2025 · CA · contact PI
Invent@SC Clinical Pharmacology of Biotherapeutics$166,192
T32 · FY2025 · GM · contact PI
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma$817,202
U01 · FY2024 · CA · contact PI
Assessing the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager in ROR1-positive and -negative neuroblastoma models$503,194
R21 · FY2024 · CA · contact PI
Immunoregulatory Mechanisms of BiTE Efficacy in the Cold Neuroblastoma TME$195,700
U01 · FY2024 · CA · contact PI
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma$860,018
U01 · FY2023 · CA · contact PI
Targeted Therapy in Ex Vivo Medulloblastoma$438,734
R01 · FY2023 · CA · contact PI
Targeted Therapy in Ex Vivo Medulloblastoma$137,426
R01 · FY2023 · CA · contact PI
Engineering Knotted Peptide Therapeutics for Pediatric Brain Tumor Patients$644,689
R01 · FY2022 · CA · contact PI
Targeted Therapy in Ex Vivo Medulloblastoma$438,736
R01 · FY2022 · CA · contact PI
Targeted Therapy in Ex Vivo Medulloblastoma/PNET$136,510
R01 · FY2022 · CA · contact PI
Engineering knotted peptide therapeutics for pediatric brain tumor patients$789,957
R01 · FY2021 · CA · contact PI
Targeted Therapy in Ex Vivo Medulloblastoma/PNET$420,660
R01 · FY2021 · CA · contact PI
Diversity Supplement to Targeted Therapy in Ex Vivo Medulloblastoma/PNET$69,886
R01 · FY2021 · CA · contact PI
Engineering knotted peptide therapeutics for pediatric brain tumor patients$793,459
R01 · FY2020 · CA · contact PI
Targeted Therapy in Ex Vivo Medulloblastoma/PNET$420,660
R01 · FY2020 · CA · contact PI
Combinations of Synergistic Bispecific Human Antibodies: A Novel Strategy for the Treatment of Neuroblastoma$176,000
U01 · FY2020 · CA · contact PI
Testing a cancer patient-specific SARS-CoV-2 vaccine in chemotherapy- and radiation-treated pediatric brain tumor mouse models$176,000
R01 · FY2020 · CA · contact PI
Engineering knotted peptide therapeutics for pediatric brain tumor patients$638,218
R01 · FY2019 · CA · contact PI
Targeted Therapy in Ex Vivo Medulloblastoma/PNET$438,710
R01 · FY2019 · CA · contact PI
Engineering knotted peptide therapeutics for pediatric brain tumor patients$65,741
R01 · FY2019 · CA · contact PI
Combinations of Synergistic Bispecific Human Antibodies: A Novel Strategy for the Treatment of Neuroblastoma$1,543,917
U01 · FY2018 · CA · contact PI
Combinations of Synergistic Bispecific Human Antibodies: A Novel Strategy for the Treatment of Neuroblastoma$702,680
U01 · FY2018 · CA · contact PI
Engineering knotted peptide therapeutics for pediatric brain tumor patients$690,368
R01 · FY2018 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$396,000
R01 · FY2018 · CA · contact PI
Arrayed drug microinjection for guiding precision medicine in relapsed lymphoma$1,002,741
R44 · FY2017 · CA
Identification of Small Molecule Inhibitors of PHF5A for Glioblastoma$525,691
R01 · FY2017 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$396,000
R01 · FY2017 · CA · contact PI
Arrayed drug microinjection for guiding precision medicine in relapsed lymphoma$1,053,521
R44 · FY2016 · CA
Identification of Small Molecule Inhibitors of PHF5A for Glioblastoma$525,944
R01 · FY2016 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$396,000
R01 · FY2016 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$227,292
R01 · FY2016 · CA · contact PI
Identification of Small Molecule Inhibitors of PHF5A for Glioblastoma$530,677
R01 · FY2015 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$396,000
R01 · FY2015 · CA · contact PI
Infant and Toddler Brain Tumors$365,200
R01 · FY2015 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$227,292
R01 · FY2015 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$396,000
R01 · FY2014 · CA · contact PI
Infant and Toddler Brain Tumors$354,244
R01 · FY2014 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$220,474
R01 · FY2014 · CA · contact PI
Infant and Toddler Brain Tumors$343,288
R01 · FY2013 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$213,654
R01 · FY2013 · CA · contact PI
Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients$652,762
R42 · FY2012 · CA · contact PI
Infant and Toddler Brain Tumors$365,200
R01 · FY2012 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$354,244
R01 · FY2012 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$227,292
R01 · FY2012 · CA · contact PI
Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients$544,375
R42 · FY2011 · CA · contact PI
Infant and Toddler Brain Tumors$365,200
R01 · FY2011 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$354,244
R01 · FY2011 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$365,200
R01 · FY2010 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$223,417
R01 · FY2010 · CA · contact PI
Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients$164,492
R42 · FY2010 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$365,200
R01 · FY2009 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$223,417
R01 · FY2009 · CA · contact PI
Chlorotoxin as a Targeting Agent for Cancer Therapies$363,308
R01 · FY2008 · CA · contact PI
bHLH Factors in Medulloblastoma Genesis and Maintenance$310,300
R01 · FY2008 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$223,417
R01 · FY2008 · CA · contact PI
bHLH Factors in Medulloblastoma Genesis and Maintenance$310,300
R01 · FY2007 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$223,417
R01 · FY2007 · CA · contact PI
bHLH Factors in Medulloblastoma Genesis and Maintenance$323,310
R01 · FY2006 · CA · contact PI
Targeted therapy in ex vivo medulloblastoma/PNET$226,761
R01 · FY2006 · CA · contact PI
bHLH Factors in Medulloblastoma Genesis and Maintenance$341,675
R01 · FY2005 · CA
Mechanisms of Gene Dysregulation in HD$432,500
R01 · FY2004 · NS
Mechanisms of Gene Dysregulation in HD$432,500
R01 · FY2003 · NS
Mechanisms of Gene Dysregulation in HD$432,500
R01 · FY2002 · NS
Mechanisms of Gene Dysregulation in HD$432,500
R01 · FY2001 · NS